✦ LIBER ✦

Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis

✍ Scribed by Saulius Girnius; David C. Seldin; Martha Skinner; Kathleen T. Finn; Karen Quillen; Gheorghe Doros; Vaishali Sanchorawala

Publisher: Springer
Year: 2009
Tongue: English
Weight: 142 KB
Volume: 89
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-009-0874-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Successful treatment of primary AL amylo

Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation

✍ Osamu Yamazaki; Yoshifumi Ubara; Tatsuya Suwabe; Shohei Nakanishi; Junichi Hoshi 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 234 KB

High-dose melphalan versus busulfan, cyc

High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma

✍ Don M. Benson Jr.; Patrick J. Elder; Thomas S. Lin; William Blum; Sam Penza; Bel 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 192 KB

Post-transplant outcomes of induction th

Post-transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support

✍ Dan T. Vogl; Stephen V. Liu; Elise A. Chong; Selina M. Luger; David L. Porter; S 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB 👁 2 views

High-dose therapy with peripheral blood

High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors

✍ K. Neben; S. Hohaus; H. Goldschmidt; G. Egerer; M. T. Voso; A. D. Ho; R. Haas 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 118 KB

Effect of high-dose melphalan and periph

Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature

✍ E. Reiter; P. Kalhs; F. Keil; W. Rabitsch; H. Gisslinger; G. Mayer; N. Worel; K. 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 49 KB

Cyclophosphamide plus dexamethasone is a

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame